Lawmakers to Teva, Mylan: Stop stonewalling our price-fixing probe | Fierce Pharma
How Mylan tried to keep Teva from selling a generic EpiPen
Teva makes $40B offer for Mylan
Teva-Makes-Hostile-Bid-Acquire
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Generic Drugmakers Mylan and Teva Face Antitrust Complaint
Mylan NV and Teva Pharmaceutical Industries Ltd decline as report says generic-drug companies face probe of alleged price fixing
Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution; Decision Prevents Approval of Teva ANDA
20 States Accuse Generic Drug Companies of Price Fixing - The New York Times
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Mylan Rejects Teva Buyout Offer
$40B deal: Teva offers to buy Mylan
Teva launches generic EpiPen in the U.S. | Fierce Biotech
Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Teva, Mylan to jumpstart production of old malaria drug to fight coronavirus
Drugmaker Teva makes $40B bid for rival Mylan
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Teva Offers to Buy Mylan for $40 Billion - WSJ
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
